These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

150 related articles for article (PubMed ID: 36225643)

  • 1.
    Wu CE; Chen CP; Pan YR; Jung SM; Chang JW; Chen JS; Yeh CN; Lunec J
    Am J Cancer Res; 2022; 12(9):4399-4410. PubMed ID: 36225643
    [TBL] [Abstract][Full Text] [Related]  

  • 2. WIP1 Inhibition by GSK2830371 Potentiates HDM201 through Enhanced p53 Phosphorylation and Activation in Liver Adenocarcinoma Cells.
    Wu CE; Huang CY; Chen CP; Pan YR; Chang JW; Chen JS; Yeh CN; Lunec J
    Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359777
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Targeting negative regulation of p53 by MDM2 and WIP1 as a therapeutic strategy in cutaneous melanoma.
    Wu CE; Esfandiari A; Ho YH; Wang N; Mahdi AK; Aptullahoglu E; Lovat P; Lunec J
    Br J Cancer; 2018 Feb; 118(4):495-508. PubMed ID: 29235570
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Chemical Inhibition of Wild-Type p53-Induced Phosphatase 1 (WIP1/PPM1D) by GSK2830371 Potentiates the Sensitivity to MDM2 Inhibitors in a p53-Dependent Manner.
    Esfandiari A; Hawthorne TA; Nakjang S; Lunec J
    Mol Cancer Ther; 2016 Mar; 15(3):379-91. PubMed ID: 26832796
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tipping Growth Inhibition into Apoptosis by Combining Treatment with MDM2 and WIP1 Inhibitors in p53
    Chamberlain V; Drew Y; Lunec J
    Cancers (Basel); 2021 Dec; 14(1):. PubMed ID: 35008180
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-delivery of p53 and MDM2 inhibitor RG7388 using a hydroxyl terminal PAMAM dendrimer derivative for synergistic cancer therapy.
    Chen K; Xin X; Qiu L; Li W; Guan G; Li G; Qiao M; Zhao X; Hu H; Chen D
    Acta Biomater; 2019 Dec; 100():118-131. PubMed ID: 31568878
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non-Small Cell Lung Cancer Xenograft Models.
    Hai J; Sakashita S; Allo G; Ludkovski O; Ng C; Shepherd FA; Tsao MS
    J Thorac Oncol; 2015 Aug; 10(8):1172-80. PubMed ID: 26200271
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The MDM2 small-molecule inhibitor RG7388 leads to potent tumor inhibition in p53 wild-type neuroblastoma.
    Lakoma A; Barbieri E; Agarwal S; Jackson J; Chen Z; Kim Y; McVay M; Shohet JM; Kim ES
    Cell Death Discov; 2015; 1():15026-. PubMed ID: 26998348
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Wip1 inhibitor GSK2830371 inhibits neuroblastoma growth by inducing Chk2/p53-mediated apoptosis.
    Chen Z; Wang L; Yao D; Yang T; Cao WM; Dou J; Pang JC; Guan S; Zhang H; Yu Y; Zhao Y; Wang Y; Xu X; Shi Y; Patel R; Zhang H; Vasudevan SA; Liu S; Yang J; Nuchtern JG
    Sci Rep; 2016 Dec; 6():38011. PubMed ID: 27991505
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The pathophysiological significance of PPM1D and therapeutic targeting of PPM1D-mediated signaling by GSK2830371 in mantle cell lymphoma.
    Kojima K; Maeda A; Yoshimura M; Nishida Y; Kimura S
    Oncotarget; 2016 Oct; 7(43):69625-69637. PubMed ID: 27626308
    [TBL] [Abstract][Full Text] [Related]  

  • 11. miR-16-5p enhances sensitivity to RG7388 through targeting
    Zanjirband M; Rahgozar S; Aberuyi N
    Cancer Drug Resist; 2023; 6(2):242-256. PubMed ID: 37457129
    [No Abstract]   [Full Text] [Related]  

  • 12. Cell Cycle Arrest and Cytotoxic Effects of SAHA and RG7388 Mediated through p21
    Natarajan U; Venkatesan T; Radhakrishnan V; Samuel S; Rasappan P; Rathinavelu A
    Medicina (Kaunas); 2019 Jan; 55(2):. PubMed ID: 30700046
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacological Inhibition of WIP1 Sensitizes Acute Myeloid Leukemia Cells to the MDM2 Inhibitor Nutlin-3a.
    Fontana MC; Nanni J; Ghelli Luserna di Rorà A; Petracci E; Padella A; Ghetti M; Ferrari A; Marconi G; Soverini S; Iacobucci I; Papayannidis C; Curti A; Audisio E; Giannini MB; Rondoni M; Lanza F; Cavo M; Martinelli G; Simonetti G
    Biomedicines; 2021 Apr; 9(4):. PubMed ID: 33917342
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pre-clinical evaluation of the MDM2-p53 antagonist RG7388 alone and in combination with chemotherapy in neuroblastoma.
    Chen L; Rousseau RF; Middleton SA; Nichols GL; Newell DR; Lunec J; Tweddle DA
    Oncotarget; 2015 Apr; 6(12):10207-21. PubMed ID: 25844600
    [TBL] [Abstract][Full Text] [Related]  

  • 15. MDM2 inhibitor RG7388 potently inhibits tumors by activating p53 pathway in nasopharyngeal carcinoma.
    Fan X; Wang Y; Song J; Wu H; Yang M; Lu L; Weng X; Liu L; Nie G
    Cancer Biol Ther; 2019; 20(10):1328-1336. PubMed ID: 31311404
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of WIP1 phosphatase sensitizes breast cancer cells to genotoxic stress and to MDM2 antagonist nutlin-3.
    Pechackova S; Burdova K; Benada J; Kleiblova P; Jenikova G; Macurek L
    Oncotarget; 2016 Mar; 7(12):14458-75. PubMed ID: 26883108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Combination treatment with rucaparib (Rubraca) and MDM2 inhibitors, Nutlin-3 and RG7388, has synergistic and dose reduction potential in ovarian cancer.
    Zanjirband M; Curtin N; Edmondson RJ; Lunec J
    Oncotarget; 2017 Sep; 8(41):69779-69796. PubMed ID: 29050241
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cooperation of Nutlin-3a and a Wip1 inhibitor to induce p53 activity.
    Sriraman A; Radovanovic M; Wienken M; Najafova Z; Li Y; Dobbelstein M
    Oncotarget; 2016 May; 7(22):31623-38. PubMed ID: 27183917
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDM2 antagonists as a novel treatment option for acute myeloid leukemia: perspectives on the therapeutic potential of idasanutlin (RG7388).
    Khurana A; Shafer DA
    Onco Targets Ther; 2019; 12():2903-2910. PubMed ID: 31289443
    [TBL] [Abstract][Full Text] [Related]  

  • 20. WIP1 phosphatase as a potential therapeutic target in neuroblastoma.
    Richter M; Dayaram T; Gilmartin AG; Ganji G; Pemmasani SK; Van Der Key H; Shohet JM; Donehower LA; Kumar R
    PLoS One; 2015; 10(2):e0115635. PubMed ID: 25658463
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.